Purchases through the above links give commission which helps fund this website
Recent literature: Dipeptidyl peptidase 4 inhibitor
Date Journal Article title
2019 Jun Clin Pharmacol Drug Dev Bioequivalence of ErtugliflozinSitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
2019 Am J Transl Res Sitagliptin ameliorates advanced glycation end-product (AGE)-induced degradation of extracellular matrix in human primary chondrocytes.
2019 Jun Australas J Dermatol Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
2019 Jun Diabetes Ther Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.
2019 Mar Pharmacol Rep DPP4 inhibitor induces beta cell regeneration and DDR-1 protein expression as an endocrine progenitor cell marker in neonatal STZ-diabetic rats.
2019 Jun Arch Gerontol Geriatr Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment.
2019 Jun Expert Opin Ther Pat Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018).
2019 Jun Neuropharmacology DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling.
2019 May J Diabetes Complications Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes.
2019 Jun Hepatol Res The combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.
2019 Jun Life Sci Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage.
2019 Apr Can J Diabetes Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
2019 Jun Eur J Pharm Sci Single-dose escalation study of yogliptin in healthy Chinese volunteers.
2019 Jun Diabetes Ther Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin's Effect to Sitagliptin on Cardiac Fat AccumulationFunction in Patients with Type 2 Diabetes.
2019 Jun Diabetes Obes Metab Do GLP-1RA and SGLT-2i reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
2019 Jun Diabetes Care Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
2019 Jun Clin Ther DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice.
2019 Jun J Eval Clin Pract Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes.
2019 May Diabetes Res Clin Pract Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes.
2019 May Diabetes Obes Metab Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial.
2019 May J Diabetes Investig Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase-4 inhibitors in treatment-naïve patients with type 2 diabetes in Japan.
2019 Diabetol Int Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study.
2019 Front Neurol Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke.
2019 Jun Pharmazie Relationship Between Initial Renal Function and the Inhibitory Effect of Dipeptidyl Peptidase-4 Inhibitor Treatment on Renal Function Decline.
2019 J Manag Care Spec Pharm Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
2019 May Int J Mol Sci The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
2019 Exp Gerontol Combined dipeptidyl peptidase-4 inhibitor with low-dose testosterone exerts greater efficacy than monotherapy on improving brain function in orchiectomized obese rats.
2019 May Diabetes Res Clin Pract CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle.
2019 Am J Manag Care Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
2019 May J Diabetes Investig Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke.
2019 Diabetes Care Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting.
2019 May Pharmazie Association between dipeptidyl peptidase-4 inhibitors and autoimmune disorders: Data mining of the spontaneous reporting system in Japan.
2019 May Pharmaceutics Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study.
2019 Am J Transl Res Sitagliptin protects against hypoxiareoxygenation (HR)-induced cardiac microvascular endothelial cell injury.
2019 May Drug Metab Dispos Identification of Novel Metabolites of Vildagliptin in Rats: Thiazoline-Containing Thiol Adducts Formed via Cysteine or Glutathione Conjugation.
2019 Arch Oral Biol Sitagliptin's effects on bone tissue and osseointegration in diabetic rats.
2019 Diabetes Obes Metab Effects of sodium-glucose cotransporter inhibitors on cardiorenal and metabolic systems: Latest perspectives from the outcome trials.
2019 May Diabetes Ther Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report.
2019 May J Clin Endocrinol Metab Sacubitrilvalsartan augments postprandial plasma concentrations of active GLP-1 when combined with sitagliptin in men.
2019 Inflamm Res The incretin enhancer, sitagliptin, exacerbates expression of hepatic inflammatory markers in rats fed a high-cholesterol diet.
2019 May Diabetes Obes Metab Identification of groups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a ervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
2019 Jun Am J Hypertens Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
2019 J Family Med Prim Care A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus.
2019 Biochem Biophys Rep Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.
2019 Xi Bao Yu Fen Zi Mian Yi ... [Sitagliptin inhibits cell apoptosis and inflammation of renal tissues in diabetic nephropathy model rats].
2019 IUBMB Life Protective effect of vildagliptin on TNF-α-induced chondrocyte senescence.
2019 Apr Exp Physiol Combined treatment of dipeptidyl peptidase-4 inhibitor and exercise training improves lipid profile in KKTa mice.
2019 J Clin Med Res Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.
2019 May Endocr J Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones.
2019 Apr Diab Vasc Dis Res Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
2019 Apr Int J Environ Res Public ... Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes.
2019 Apr Cochrane Database Syst Rev Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
2019 Apr Diabetes Obes Metab Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
2019 Lancet Diabetes Endocrinol Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
2019 Apr J Diabetes Investig Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology.
2019 Drugs The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
2019 Kidney Int Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 56 nephrectomy.
2019 Apr Clin Exp Hypertens Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
2019 Apr Br J Clin Pharmacol Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
2019 Jun Circulation Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
2019 Diabetes Res Clin Pract Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
2019 Artif Cells Nanomed Biote... The protective effects of saxagliptin against lipopolysaccharide (LPS)-induced inflammation and damage in human dental pulp cells.
2019 Apr Pharmazie The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice iviai inhibiting the TGF-βSmad signal pathway.
2019 Diabetes Ther Acquired Hemophilia A Associated with Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Single-Center Case Series in Japan.
2019 Feb Acta Histochem Cytochem Immunohistochemistry for Anti-diabetes Drug, Alogliptin Using a Newly Prepared Monoclonal Antibody: Its Precise Localization in Rat Small Intestine.
2019 Mar EBioMedicine Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis.
2019 Endocrinol Metab (Seoul) Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea.
2019 Diabetes Res Clin Pract Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.
2019 Mar Sci Rep Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity.
2019 Diabetes Care The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
2019 Apr J Agric Food Chem A Supramolecular Approach to Develop New Soybean and Lupin Peptide Nanogels with Enhanced Dipeptidyl Peptidase IV (DPP-IV) Inhibitory Activity.
2019 Feb Diabetes Metab J Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study.
2019 Mar BMC Cardiovasc Disord Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
2019 Mar Int J Mol Sci Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes.